ホーム>>Histone H3K27Me1 (21-44)-GK-biotin (trifluoroacetate salt)

Histone H3K27Me1 (21-44)-GK-biotin (trifluoroacetate salt) (Synonyms: ATKAAR-K(Me1)-SAPATGGVKKPHRYRPG-GK(Biotin), Lys(Me1)27-Histone H3 (21-44)-GK(Biotin), Histone H3 (21-44) (Lys27me1))

カタログ番号GC43845

Histone H3K27Me1(21-44)-GK-biotinは、ヒトヒストンH3.1およびH3.2配列のアミノ酸残基22〜45に対応するヒストンH3のペプチドフラグメントです。

Products are for research use only. Not for human use. We do not sell to patients.

Histone H3K27Me1 (21-44)-GK-biotin (trifluoroacetate salt) 化学構造

サイズ 価格 在庫数 個数
250μg
$335.00
在庫あり

Tel:(909) 407-4943 Email: sales@glpbio.com

顧客レビュー

カスタマーレビューに基づきます。

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Histone H3K27Me1 (21-44)-GK-biotin is a peptide fragment of histone H3 that corresponds to amino acid residues 22-45 of the human histone H3.1 and H3.2 sequences. It is monomethylated at lysine 27 and biotinylated via a C-terminal GK linker. Monomethylation of histone H3 at lysine 27 is associated with actively transcribed genes and positively correlates with H3K36 trimethylation. Levels of H3K27Me1 are increased in tumor tissue isolated from patients with metastatic hormone-na?ve and castration-resistant prostate cancer. Histone H3K27Me1 (21-44)-GK-biotin has been used in a high-throughput screen for inhibitors of the histone demethylase jumonji AT-rich interactive domain 1B (JARID1B).

レビュー

Review for Histone H3K27Me1 (21-44)-GK-biotin (trifluoroacetate salt)

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Histone H3K27Me1 (21-44)-GK-biotin (trifluoroacetate salt)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.